Rocket Pharmaceuticals received the rare pediatric disease priority review voucher with the accelerated FDA approval for Kresladi in March. The non-dilutive capital from the voucher’s sale will support a pipeline that includes a gene therapy in pivotal clinical testing for the rare genetic disorder Danon disease. The post Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass appeared first on MedCity News .
The industry needs a framework that can translate clinical nuance into a consistent, trusted representation across systems and use cases. The post In the Age of AI, Interoperability Isn’t Enough: Why Healthcare Needs Shared Understanding, Not Just Shared Data appeared first on MedCity News .
(MedPage Today) -- Over the next month, millions of fans will gather across North America for the FIFA World Cup. Stadiums will fill with cheering crowds. Young athletes will dream of representing their countries one day. Communities will celebrate...
The gap between how nicotine use has evolved and how cessation treatment has evolved is a meaningful part of why quit rates have plateaued. The post Smoking Cessation’s Quiet Design Failure appeared first on MedCity News .
Telehealth companies offer lifestyle support so people taking obesity drugs can have the most success losing weight. But employers also want the telehealth providers to limit spending on the drugs.
(MedPage Today) -- CHICAGO -- Use of GLP-1 receptor agonists was tied to significantly lower risks of major diabetic foot complications compared with SGLT2 inhibitors in adults with type 2 diabetes, a large, real-world analysis indicated. Compared...
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
(MedPage Today) -- For years, physicians have voiced the same frustrations: declining reimbursement, increasing administrative burden, private equity infiltration, insurance company control, expanding scope creep, artificial intelligence (AI) anxiety...
(MedPage Today) -- Fruit-flavored e-cigarettes recently authorized by the FDA were not significantly better at helping smokers quit than tobacco-flavored e-cigarettes, according to a new memo that's likely to stir new questions about the agency...